Arcus Biosciences (RCUS) Projected to Announce Quarterly Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is expected to be posting its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Arcus Biosciences to post earnings of ($0.8912) per share and revenue of $22.2150 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The company had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business’s quarterly revenue was down 39.3% on a year-over-year basis. During the same period last year, the firm posted ($1.14) EPS. On average, analysts expect Arcus Biosciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arcus Biosciences Stock Down 1.7%

Shares of NYSE:RCUS opened at $27.70 on Tuesday. Arcus Biosciences has a 52-week low of $8.88 and a 52-week high of $31.74. The stock has a market cap of $3.48 billion, a P/E ratio of -8.71 and a beta of 0.80. The business has a fifty day moving average of $27.09 and a two-hundred day moving average of $24.11. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RCUS. Wall Street Zen cut shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Morgan Stanley raised their price objective on shares of Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Friday, July 17th. HC Wainwright boosted their target price on shares of Arcus Biosciences from $32.00 to $45.00 and gave the company a “buy” rating in a report on Monday, July 20th. Finally, Leerink Partners set a $47.00 price target on shares of Arcus Biosciences in a research note on Monday, April 20th. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.40.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,562 shares of Arcus Biosciences stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $25.77, for a total value of $66,022.74. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,020,002.37. The trade was a 6.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 48,502 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $30.05, for a total transaction of $1,457,485.10. Following the sale, the president owned 842,307 shares in the company, valued at $25,311,325.35. This trade represents a 5.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 110,325 shares of company stock worth $3,174,319 in the last three months. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arcus Biosciences

Several large investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC lifted its holdings in Arcus Biosciences by 40.7% during the 4th quarter. Suvretta Capital Management LLC now owns 5,188,858 shares of the company’s stock worth $123,650,000 after buying an additional 1,500,000 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Arcus Biosciences by 309.4% in the fourth quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company’s stock worth $123,547,000 after acquiring an additional 3,918,220 shares in the last quarter. State Street Corp increased its position in shares of Arcus Biosciences by 34.8% during the fourth quarter. State Street Corp now owns 4,576,969 shares of the company’s stock worth $109,069,000 after acquiring an additional 1,182,115 shares during the period. Marshall Wace LLP purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth $80,731,000. Finally, Siren L.L.C. raised its stake in shares of Arcus Biosciences by 3.3% in the fourth quarter. Siren L.L.C. now owns 3,007,077 shares of the company’s stock valued at $71,659,000 after acquiring an additional 95,000 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.